Literature DB >> 6381183

Impaired insulin action in rats with non-insulin-dependent diabetes.

J Levy, J R Gavin, A Fausto, R L Gingerich, L V Avioli.   

Abstract

Studies were performed to test the hypothesis that impaired insulin action occurs as an acquired phenomenon in the streptozocin (STZ)-treated, non-insulin-dependent (NIDDM) diabetic rat model. A number of methods were used to evaluate impaired carbohydrate tolerance in these animals. Plasma glucose and insulin levels were measured at 6 and 14 wk of age, and insulin glucose tolerance tests were performed at 4 and 5 wk of age (before overt hyperglycemia ensues), and at 8 and 14 wk of age (after the animals manifest overt diabetes). The STZ-treated rats had higher plasma glucose levels than those of control animals (P less than 0.001) at 6 and 14 wk of age, while their plasma insulin values were decreased to levels 73% of the controls (1.7 ng/ml versus 2.3 ng/ml, P less than 0.04). Glucose disappearance rates after high (0.35 U/kg) and low (0.175 U/kg) insulin challenge were reduced in the experimental diabetic animals at all ages with both insulin doses. The data suggest that these animals have an early and progressive acquired impairment in insulin action, most compatible with a defect in cellular biologic response to insulin. The possibility that this abnormality is secondary to insulin deficiency is raised.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6381183     DOI: 10.2337/diab.33.9.901

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

1.  Plasma membrane phospholipid content in non-insulin-dependent streptozotocin-diabetic rats--effect of insulin.

Authors:  J Levy; Y Suzuki; L V Avioli; G Grunberger; J R Gavin
Journal:  Diabetologia       Date:  1988-05       Impact factor: 10.122

2.  V-ATPase blockade reduces renal gluconeogenesis and improves insulin secretion in type 2 diabetic rats.

Authors:  Jun Hirao; Akihiro Tojo; Saaya Hatakeyama; Hiroshi Satonaka; Toshihiko Ishimitsu
Journal:  Hypertens Res       Date:  2020-05-08       Impact factor: 3.872

3.  In vivo insulin antagonism but evanescent in vitro tissue effect in rats with growth hormone-secreting tumors.

Authors:  M B Davidson; D C Shen; N Venkatesan; G Sladen
Journal:  J Endocrinol Invest       Date:  1987-12       Impact factor: 4.256

4.  Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle.

Authors:  L Rossetti; M R Lauglin
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

5.  Physiologic and cellular insulin action in a glucose-intolerant model of type 2 (non-insulin-dependent) diabetes in rats.

Authors:  B L Maloff; B K Boyd
Journal:  Diabetologia       Date:  1986-05       Impact factor: 10.122

6.  Liver and muscle insulin sensitivity, glycogen concentration and glycogen synthase activity in a rat model of non-insulin-dependent diabetes.

Authors:  Y T Kruszynska; P D Home
Journal:  Diabetologia       Date:  1988-05       Impact factor: 10.122

7.  Blood levels of insulin-like growth factors I and II in neonates of non-insulin-dependent diabetic rats.

Authors:  J Levy; J R Gavin
Journal:  Acta Diabetol       Date:  1994-09       Impact factor: 4.280

8.  Parathyroid hormone decreases in vivo insulin effect on glucose utilization.

Authors:  A W Saxe; G Gibson; R L Gingerich; J Levy
Journal:  Calcif Tissue Int       Date:  1995-08       Impact factor: 4.333

9.  Abnormal cell calcium concentrations in cultured bone cells obtained from femurs of obese and noninsulin-dependent diabetic rats.

Authors:  J Levy; I Reid; L Halstad; J R Gavin; L V Avioli
Journal:  Calcif Tissue Int       Date:  1989-02       Impact factor: 4.333

10.  The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats.

Authors:  G Lisato; I Cusin; A Tiengo; S Del Prato; B Jeanrenaud
Journal:  Diabetologia       Date:  1992-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.